ArticleSchizophrenia bulletin2011
Presynaptic regulation of dopamine transmission in schizophrenia.
Article in Schizophrenia bulletin, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 6 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- From risk to chronicity: genetic and neuroimaging insights into the evolving patterns of spontaneous brain activity in schizophrenia.Psychological medicine · 2025Pooled it
- The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review.Translational psychiatry · 2017Pooled it
- Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis.Schizophrenia bulletin · 2013Pooled it
- Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.Schizophrenia bulletin · 2013Pooled it
- Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.Schizophrenia bulletin · 2013Pooled it
- The nature of dopamine dysfunction in schizophrenia and what this means for treatment.Archives of general psychiatry · 2012Pooled it
- Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysis.Schizophrenia (Heidelberg, Germany) · 2025Review
- Direct Pathway Neurons in the Mouse Ventral Striatum Are Active During Goal-Directed Action but Not Reward Consumption During Operant Conditioning.Biomedicines · 2024Article
- Parvalbumin interneuron deficits in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024Review
- Psychosis in Spinocerebellar Ataxias: a Case Series and Study of Tyrosine Hydroxylase in Substantia Nigra.Cerebellum (London, England) · 2018Article
- Article
- Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.Schizophrenia bulletin · 2017Article
- Abnormally Increased Secretion in Olfactory Neuronal Precursors from a Case of Schizophrenia Is Modulated by Melatonin: A Pilot Study.International journal of molecular sciences · 2017Article
- Presynaptic and extrasynaptic regulation of posterior nucleus of thalamus.Journal of neurophysiology · 2017Article
- Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.Biological psychiatry · 2017Review
- Model-based optimization approaches for precision medicine: A case study in presynaptic dopamine overactivity.PloS one · 2017Article
- Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.Translational psychiatry · 2016Article
- Physiological and behavioral effects of amphetamine in BACE1(-/-) mice.Genes, brain, and behavior · 2015Article
- Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.Neurotoxicity research · 2014Review
- Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits.Molecular psychiatry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
A role for dopamine (DA) release in the hallucinations and other positive symptoms associated with schizophrenia has long been inferred from the antipsychotic response to D2 DA receptor antagonists and because the DA releaser amphetamine can be psychotogenic. Recent studies suggest that patients with schizophrenia, including those never exposed to antipsychotic drugs, maintain high presynaptic DA accumulation in the striatum. New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.